SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Leonard Nimoy — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLeonard Nimoy
Date of birth1931-03-26
IdentifiersMRN HR-ML017-SYN-TD; SSN (made up) 000-17-6604
Document date2014-05-12
AuthorCarla Benedetti, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month COPD review after pulmonary rehabilitation. [S]

History of Present Illness

Mr. Nimoy returns three months after starting tiotropium-olodaterol and four days after finishing pulmonary rehabilitation. He attended all 24 sessions. He now walks about 300 meters at his own pace before stopping, uses the pursed-lip breathing he learned there, and has a home program of walking twice a day and strength exercises three times a week. He uses albuterol about twice a week, mostly before longer walks. He has taken every maintenance dose. He has had no flare-up, antibiotic or prednisone course, or emergency visit. He repeated the 6-minute walk in the pulmonary function laboratory this morning. The pneumococcal vaccine that was out of stock at the last visit is available today. [S]

ElementDetail
RehabilitationCompleted 24 of 24 sessions four days ago; home program in place
Exercise toleranceWalks about 300 meters before stopping
Reliever useAlbuterol about twice a week
AdherenceAll maintenance doses taken
ExacerbationsNone

Review of Systems

SystemResultFinding
RespiratoryPositiveBreathless after about 300 meters or a flight of stairs; no increase in cough or sputum
CardiovascularNegativeNo chest pain, palpitations, or ankle swelling
MusculoskeletalNegativeNo injuries or joint pain from the exercise program

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake)Two inhalations every 4 hours as needed, with a spacerRespiratory tract route2013-09-15activeS
Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once dailyTwo inhalations once each morningRespiratory tract route2014-02-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2014-05-12Body height185cmS
2014-05-12Body weight80.8kgS
2014-05-12Body mass index (BMI) [Ratio]23.6kg/m2S
2014-05-12Systolic blood pressure126mm[Hg]S
2014-05-12Diastolic blood pressure76mm[Hg]S
2014-05-12Heart rate78/minS
2014-05-12Respiratory rate18/minS
2014-05-12Body temperature36.7CelS
2014-05-12Oxygen saturation in Arterial blood by Pulse oximetry94%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2014-05-12Six minute walk test330mPredicted about 480 m for his age, sex, height, and weight; lower limit about 380 mLowS

Physical Exam

Vital signs recorded on 2014-05-12; see the Vital Signs section. [S]

SystemFinding
GeneralComfortable at rest; speaks in full sentences
LungsReduced breath sounds with prolonged expiration; no wheeze or crackles
CardiovascularRegular rhythm at 78 per minute; no edema
Inhaler techniqueCorrect with his soft mist inhaler

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic obstructive pulmonary disease, GOLD 3 (severe airflow limitation), group B, confirmed on spirometry; synthetic modern classification linked to his publicly disclosed COPDactiveconfirmed J44.9S — Synthetic modern spirometric classification; the COPD diagnosis itself is D from his own public disclosure.
Former smoker, quit about 30 years ago through a cessation programactiveconfirmed Z87.891S — Synthetic modern entry linked to his public account of quitting smoking.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyCOPD Assessment Test (CAT)Every visitCompleted today15, down from 19 at four weeks and 22 at intake
SurveymMRC dyspnea gradeEvery visitCompleted todayGrade 2, down from 3
SurveyExacerbation history and GOLD groupEvery visitCompleted todayNone; group B
ExaminationPulse oximetryEvery visitCompleted today94 percent at rest on room air
Self-managementSmoking status and cessation supportEvery visitCompleted todayFormer smoker; no tobacco
ExaminationBMI and nutritional statusEvery visitCompleted todayBMI 23.6; weight up 0.6 kg with exercise
ExaminationInhaler technique and adherenceEvery visitCompleted todayCorrect; full adherence
Examination6-minute walk testAt pulmonary rehabilitation entry and exit, and for oxygen assessmentCompleted today330 m at rehabilitation exit, up 60 m; lowest saturation 90 percent
ExaminationLong-term oxygen assessmentAs indicated: resting saturation 88 percent or less, confirmed twice at least three weeks apartNot indicatedResting saturation 94 percent; no oxygen criterion met
ReferralPulmonary rehabilitationStable mMRC 2 or more or CAT 10 or more; within three weeks of any hospital stay for an exacerbationCompleted todayProgram completed four days ago, 24 of 24 sessions; home program and maintenance class offered
ExaminationSpirometryAt diagnosis, then at least yearly and with significant clinical changeUp to dateNext in nine months, at the yearly review
LaboratoryBlood eosinophil countAt baseline and when an inhaled corticosteroid is consideredNot indicatedNo change in inhaled corticosteroid being considered
Medication safetyVaccination statusReviewed yearlyCompleted todayPCV20 given today, nine weeks later than planned. Deviation: the dose planned at the four-week visit was missed because the vaccine was out of stock. No harm resulted: he had no respiratory infection in the interval. Corrective action: vaccine stock is checked before a planned dose is booked, and missed doses are added to the next visit's orders

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]

Guideline basis: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020); Adult Immunization Schedule by Age (2026)

Follow-up: COPD review in three months, or the same day for any flare-up. Next scheduled visit 2014-08-11: six-month COPD review. [S]